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MicroRNA-29a activates a multi-component
growth and invasion program in
glioblastoma
Yun Zhao2,4, Wei Huang2, Tae-Min Kim3, Yuchae Jung2, Lata G. Menon2, Hongyan Xing2, Hongwei Li2,
Rona S. Carroll1,2, Peter J. Park3, Hong Wei Yang1,2* and Mark D. Johnson1,2,5,6*
Abstract
Background: Glioblastoma is a malignant brain tumor characterized by rapid growth, diffuse invasion and
therapeutic resistance. We recently used microRNA expression profiles to subclassify glioblastoma into five
genetically and clinically distinct subclasses, and showed that microRNAs both define and contribute to the
phenotypes of these subclasses. Here we show that miR-29a activates a multi-faceted growth and invasion program
that promotes glioblastoma aggressiveness.
Methods: microRNA expression profiles from 197 glioblastomas were analyzed to identify the candidate miRNAs
that are correlated to glioblastoma aggressiveness. The candidate miRNA, miR-29a, was further studied in vitro and
in vivo.
Results: Members of the miR-29 subfamily display increased expression in the two glioblastoma subclasses with
the worst prognoses (astrocytic and neural). We observed that miR-29a is among the microRNAs that are most
positively-correlated with PTEN copy number in glioblastoma, and that miR-29a promotes glioblastoma growth and
invasion in part by targeting PTEN. In PTEN-deficient glioblastoma cells, however, miR-29a nevertheless activates
AKT by downregulating the metastasis suppressor, EphB3. In addition, miR-29a robustly promotes invasion in PTEN-
deficient glioblastoma cells by repressing translation of the Sox4 transcription factor, and this upregulates the
invasion-promoting protein, HIC5. Indeed, we identified Sox4 as the most anti-correlated predicted target of miR-
29a in glioblastoma. Importantly, inhibition of endogenous miR-29a decreases glioblastoma growth and invasion in
vitro and in vivo, and increased miR-29a expression in glioblastoma specimens correlates with decreased patient
survival.
Conclusions: Taken together, these data identify miR-29a as a master regulator of glioblastoma growth and
invasion.
Keywords: miR-29a, Glioblastoma, Invasion, Sox4, PTEN
Background
MicroRNAs are short (about 22 nucleotides) non-coding
RNAs that generally repress translation by targeting com-
plementary sequences in the 3′ untranslated region
(3’-UTR) of messenger RNAs [1]. A single microRNA can
target dozens of messenger RNAs, thereby regulating
complex biological processes. Numerous reports have de-
tailed the important role that microRNAs play in develop-
ment and in carcinogenesis [2–4]. Because the function of
microRNAs is determined in part by the co-expression of
their specific target mRNAs, their roles are complex and
tissue specific. One striking example of this tissue-specific
complexity is miR-29a, which has widely been reported to
be a tumor suppressor in acute myeloid leukemia [5],
lymphoma [6–8], hepatocellular carcinoma [9, 10] and
gastric cancer [11, 12]. However, other studies have re-
ported an oncogenic role for miR-29a in acute myeloid
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leukemia [13] and chronic lymphocytic leukemia [14].
Likewise, miR-29a has been reported to either decrease in-
vasion in human carcinoma cell lines [15] or to increase
invasion in human epithelial cancers [16] and in human
hepatoma cells [17]. Thus, it is essential that the role of in-
dividual microRNAs such as miR-29a be evaluated in their
native context, as tissue-specific or cell type-specific gene
expression patterns have a tremendous impact on their
function.
One of the cancers where microRNAs have been
shown to play an important role is glioblastoma, the
most common and most malignant intrinsic brain tumor
[18–21]. Despite treatment, the median survival of pa-
tients with glioblastoma is only 14 to16 months and, at
present, there is no cure [22]. Recent studies have used
molecular features to divide glioblastomas into several
subclasses [19, 23–25]. We recently used microRNA ex-
pression profiles to classify glioblastoma into five genet-
ically and clinically distinct subclasses, and showed that
microRNAs contribute significantly to the phenotypic
characteristics of each subclass [19]. Although a growing
number of microRNAs have been implicated in glio-
blastoma, the functional role of a majority of these mole-
cules remains unknown.
Here we report that miR-29a is expressed primarily in
the most aggressive glioblastoma subclasses, and its ex-
pression correlates with short patient survival. miR-29a
downregulates PTEN, EphB3 and SOX4 expression to ac-
tivate a complex post-transcriptional program of growth
and invasion in glioblastoma. Antagonism of miR-29a in-
hibits glioblastoma growth and invasion in vitro and in
vivo, suggesting that this approach may represent a novel
therapeutic strategy in glioblastoma.
Methods
Lentiviruses and cell lines
All studies involving primary human tissues were con-
ducted under the auspices of a human subjects protocol
approved by the Institutional Review Board at Brigham
and Women’s Hospital. Primary glioblastoma stem-like
cells were prepared from surgical glioblastoma speci-
mens as described previously [26]. Human U87, U251
and LN229 glioblastoma cell lines were purchased from
the American Tissue Type Culture Collection. The
hsa-miR-29a sequence with ~ 264 bp of flanking se-
quence was cloned from human genomic DNA by PCR
and confirmed by DNA sequencing. The forward primer
was 5′-gcacctcgattagttctcg-3′, and the reverse primer
was 5′-ccaagctggcctaacttcag-3′. The PCR product was
transferred into the pLenti6-IRES-GFP vector and pack-
aged in 293FT cells [19]. A control EGFP lentivirus lack-
ing a microRNA sequence was also prepared. miR-29a
sponge (miR-Locker) and control sponge lentiviral vec-
tors were purchased from Biosettia and packaged in
293FT cells. LN229 and U251 glioblastoma (GBM) cells
were transduced with the control, miR-29a or miR-29a
sponge lentiviruses, and stable cell lines were selected
using blasticidin.
Genome-scale expression data and analysis
Array comparative genomic hybridization (CGH), micro-
RNA, mRNA and clinical data for 197 GBM patients
were downloaded from The Cancer Genome Atlas pro-
ject data portal (http://cancergenome.nih.gov) in March
2009. Data use certification was obtained for the use of
controlled-access data. Details on the processing and
platforms used, as well as the methods for selection of
highly informative microRNAs and consensus clustering
are as described previously [19]. In brief, we used the
online website http://www.microrna.org/microrna/
home.do to identify potential targets and looked at other
anti-correlative targets using The Cancer Genome Atlas
(TCGA) dataset. Additional data from TCGA for
Kaplan-Meier survival analyses for Sox4 and HIC5 was
obtained at http://hgserver1.amc.nl/cgi-bin/r2/main.cgi.
Luciferase reporter assays
Reporter constructs were generated by overexpressing a
vector in which firefly luciferase was fused to the Sox4
3’-UTR containing the putative miR-29a binding site
(Addgene). Expression of the luciferase fusion protein in
293 T cells was then determined as we have described
previously [27] in the presence of a miR-29a mimic (100
nM), a control oligonucleotide (100 nM) or a miR-335
mimic (as a positive control).
RNAi studies
A miRIDIAN double-stranded RNA miR-29a mimic and
a hairpin inhibitor (antagomiR) for miR-29a, as well as
the corresponding negative controls, were purchased
from Dharmacon. SOX4 siRNA and a matched oligo-
nucleotide control were purchased from Invitrogen. The
miR-29a mimic or inhibitor was added to the medium at
a concentration of 100 nM without the use of additional
transfection reagents for 48 h prior to performing assays.
For SOX4, EphB3 and HIC5 siRNA experiments, the
siRNAs were purchased from Ambion. Oligofectamine
was used to transiently transfect the cells overnight prior
to performing siRNA assays.
Real-time polymerase chain reaction (PCR)
Total RNA enriched for microRNA was extracted from
LN229 or U251 GBM cell lines using a commercially avail-
able kit (Qiagen). cDNA was then prepared using 1 μg of
total RNA from each sample (SuperScript III First-Strand
Synthesis SuperMix, Invitrogen). A miR-29a-specific
Real-time PCR primer was purchased from Applied Biosys-
tems. Six nanograms of cDNA were used for real-time PCR
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analysis in a final reaction volume of 20 uL. The samples
were analyzed in triplicate using an ABI 7300 Real-time
PCR machine, and statistical analysis was performed using
the t test.
Western blots
Western blots were performed as described previously
[27]. Briefly, total protein was extracted by RIPA buffer
and separated by gel electrophoresis. The protein was
then transferred to nitrocellulose membranes and
probed overnight using the appropriated primary anti-
bodies. The antibodies used were PTEN, SOX4, EphB3
(Abcam); HIC5 (BD Biosciences); AKT, phosphorylated
AKT (ser473), GSK3β, phosphorylated GSK3β (ser9), (Cell
Signaling); β-catenin and β-actin (Sigma). After incubation
in the appropriate secondary antibodies, immunoreactive
bands were visualized using chemiluminescence.
In vitro proliferation, growth, apoptosis and invasion
assays
Cell growth or cell survival after DNA damage were
assayed in vitro using the MTT assay, and cell prolifera-
tion was measured using bromodeoxy-uridine (BrdU) in-
corporation into DNA as we have described previously
[27]. Matrigel transwell invasion assays were performed
as we have described previously [28].
In vivo tumor growth assay
All animal studies were conducted under the auspices of
an IACUC protocol approved by the Harvard Medical
Area Standing Committee on Animals. Human LN229
glioblastoma cells were transduced with either a miR-29a
lentivirus or a control virus, and stable cell lines were
established. 5 × 106 control or miR-29a expressing glio-
blastoma cells were then injected subcutaneously into
nude mice (n = 6 animals per condition). Subcutaneous
tumor growth was then measured serially, and tumor vol-
ume was calculated using the formula for a spheroid. Sig-
nificance was determined using an upaired t-test.
Intracranial invasion assay
U251 glioblastoma cells were transduced with either a
miR-29a sponge lentivirus encoding Green Fluorescent
Protein (GFP) or a control sponge lentivirus encoding
Red Fluorescent Protein (RFP). The green or red color
was reinforced by DiO (green) or DiI (red) staining.
Control and miR-29a sponge-expressing cells were
mixed in a 1:1 ratio, and 2 × 105 cells were then injected
intracranially into nude mice. After 1 week, the animals
were sacrificed and the brains were sectioned and proc-
essed for immunofluorescence imaging. The extent of
radial invasion by glioblastoma cells transduced with the
miR-29a sponge lentivirus (green) versus the control
sponge lentivirus (red) was then assessed.
Results
miR-29a promotes glioblastoma growth
We previously reported that patients with glioblastomas
from the astrocytic and neural glioblastoma subclasses
have the shortest survival among glioblastoma patients
[19]. In the current study, we set out to identify micro-
RNAs that contribute most significantly to the aggressive
characteristics of these glioblastoma subclasses. We ana-
lysed microRNA expression profiles from 197 glioblast-
omas, and observed that members of the miR-29
subfamily (miR-29a, miR-29b, and miR-29c) were unique
among the 171 informative microRNAs examined in that
they showed a selective increase in expression in both
the astrocytic and neural glioblastoma subclasses
(Fig. 1A). Patients harboring glioblastomas from either
of these two subclasses displayed the shortest median
survival (Fig. 1B). We therefore examined the effects of
microRNA mimics for miR-29a, miR-29b and miR-29c
on proliferation in human U87 glioblastoma cells, and
found that only the miR-29a mimic significantly in-
creased proliferation (Fig. 1C, P = 0.026, unpaired t-test).
Consequently, we selected miR-29a for further study.
To determine the effect of miR-29a on glioblastoma
tumor growth in vivo, we used lentiviral transduction to
overexpress the miR-29a transcript in human LN229
glioblastoma cells. This afforded an approximately 2 fold
increase in miR-29a expression in the cells (Additional
file 1: Figure S1). Overexpression of miR-29a signifi-
cantly increased the growth of LN229 glioblastoma cells
in vitro (Fig. 1D, P < 0.02, unpaired t-test). LN229 glio-
blastoma cells transduced with the miR-29a lentivirus or
a control lentivirus were subsequently transplanted sub-
cutaneously into nude mice and tumor growth was
monitored over time. LN229 glioblastoma cells overex-
pressing miR-29a formed significantly larger tumors
than cells transduced with a control lentivirus (Fig. 2A,
P < 0.05, unpaired t-test). These data indicated that
miR-29a promotes glioblastoma growth.
miR-29a targets PTEN in glioblastoma
We next investigated the mechanisms by which miR-29a
increases glioblastoma growth. miR-29a has previously
been reported to directly target the 3’-UTR of the PTEN
tumor suppressor in hepatoma cells in vitro [17] and in
neural stem cells [29]. PTEN is frequently mutated or de-
leted in glioblastoma, and we and others have reported
that it is a target of oncogenic microRNAs in this tumor
[30–32]. PTEN loss increases glioblastoma growth and in-
vasion in part by activating the PI3 kinase/AKT pathway
[33]. Western blot analysis indicated that miR-29a down-
regulates PTEN protein expression in LN229 glioblastoma
cells and in primary glioblastoma stem-like cells (GSCs,
Fig. 2B). As expected, the miR-29a-mediated repression of
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PTEN expression was accompanied by activation of AKT
(Fig. 2C).
Integrated copy number, mRNA and microRNA ex-
pression analysis using data from 197 TCGA glioblast-
oma specimens failed to demonstrate an anti-correlation
between mir-29a and PTEN mRNA expression (Pearson
correlation coefficient (PCC) =0.038). Strikingly, how-
ever, miR-29a and its subfamily members (miR-29b and
miR-29c) were foremost among microRNAs that were
positively correlated with PTEN copy number (Fig. 2D,
PCC = 0.219 for miR-29a). Thus, miR-29a is well posi-
tioned to suppress PTEN expression in glioblastomas in
which the PTEN gene is intact.
miR-29a decreases EphB3 to increase AKT in PTEN-
deficient glioblastoma cells
Our earlier finding that miR-29a increased the prolifera-
tion of human U87 glioblastoma cells (which lack func-
tional PTEN) suggested the existence of additional
mediators of miR-29a-induced glioblastoma growth (see
Fig. 1C). To investigate this possibility further, we
examined the effect of miR-29a on the growth of human
U251 glioblastoma cells, which also lack functional
PTEN. Lentiviral-mediated overexpression of miR-29a
increased U251 glioblastoma cell proliferation signifi-
cantly (Fig. 3A, P < 0.0005, unpaired t-test). Conversely,
exposure of PTEN-deficient U251 cells to the miR-29a
inhibitor (100 nM) significantly decreased proliferation
(Fig. 3B, P < 0.05, unpaired t-test). Additionally, inhib-
ition of endogenous miR-29a using the miR-29a inhibi-
tor (100 nM) significantly decreased the growth of
PTEN-deficient U251 glioblastoma cells (Fig. 3C, P <
0.01, unpaired t-test).
In order to identify growth-promoting pathways acti-
vated by miR-29a in the absence of PTEN, we exposed
PTEN-deficient U251 glioblastoma cells to a miR-29a
mimic (100 nM), collected the protein and examined the
lysates using an antibody array that assays several key
growth regulatory pathways in the cell (Human
Phospho-Kinase Array Kit, R&D Systems). This assay re-
vealed that miR-29a increased AKT phosphorylation and
β-catenin expression in U251 glioblastoma cells, and this
Fig. 1 miR-29a is preferentially expressed in the most aggressive glioblastoma subclasses and promotes glioblastoma growth: a) Consensus clustering
microRNA expression heatmap using 121 highly informative microRNA expression profiles from 197 glioblastomas demonstrating the expression of
miR-29a (arrow) in the astrocytic and neural subclasses. The microRNA based classification of the tumor specimens is indicated at the top of the
diagram, and the mRNA-based classification is indicated at the bottom. b) Median survival of each of the microRNA-based glioblastoma subclasses. c)
BrdU proliferation assay illustrating the effect of miR-29a, miR-29b, miR-29c or a control mimic (100 nM) on proliferation in human U87 glioblastoma
cells. Mean ± SEM (*P< 0.026, unpaired t-test). d) MTT cell growth assay illustrating the effect of lentiviral-mediated overexpression of miR-29a or a
control sequence on the growth of primary human glioblastoma stem-like cells (*P < 0.0001, unpaired t-test)
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was confirmed by Western blot (Fig. 4A). AKT can
phosphorylate and inactivate GSK3β [34] which, in turn,
phosphorylates β-catenin and targets it for degradation
[35]. Indeed, miR-29a induced inhibitory phosphoryl-
ation of GSK3β on serine 9 (Fig. 4B), suggesting that the
increased β-catenin expression observed in the presence
of miR-29a may result from AKT-dependent phosphor-
ylation and inhibition of GSK3β activity.
In order to identify upstream mediators of the effect of
miR-29a on AKT activation, we identified predicted
anti-correlated mRNA targets of miR-29a using micro-
RNA and mRNA expression profiles from 261 TCGA
glioblastoma specimens. We identified EphB3 as an
anti-correlated (PCC = − 0.508) predicted target of
miR-29a. EphB3 encodes a receptor tyrosine kinase that
suppresses AKT activation in lung cancer cells [26].
Western blot confirmed decreased EphB3 expression in
human U251, LN229 and U87 cells transduced with the
miR-29a lentivirus (Fig. 4C). Moreover, siRNA-mediated
knockdown of EphB3 in LN229 glioblastoma cells in-
creased AKT phosphorylation and activation (Fig. 4D).
Thus, miR-29a decreases EphB3 expression to activate
AKT in glioblastoma.
In addition to their effects on proliferation, both AKT
and β-catenin can inhibit apoptosis in glioblastoma cells
[26, 27]. Enforced overexpression of β-catenin increased
glioblastoma cell growth (Fig. 4E, P < 0.05, unpaired
t-test). We therefore examined the effect of miR-29a on
the survival of PTEN-deficient U251 glioblastoma cells
after DNA damage. The miR-29a mimic (100 nM) signifi-
cantly increased cell growth under basal conditions and
increased survival after exposure to the DNA-damaging
agent, camptothecin (Fig. 4F, P < 0.006, unpaired t-test).
Taken together, these data suggest that miR-29a decreases
EphB3 to activate the PI3K/AKT and Wnt pathways,
thereby promoting proliferation and survival in glioblast-
oma cells.
miR-29a targets Sox4 to promote invasion in PTEN-
deficient glioblastoma cells
PTEN is a major regulator of invasion in glioblastoma
and other cancers [36]. Our finding that miR-29a targets
Fig. 2 miR-29a downregulates PTEN in glioblastoma cells. a) LN229 glioblastoma cells transduced with a miR-29a lentivirus or a control virus were
transplanted subcutaneously into nude mice (n = 8 animals/group), and tumor volume was measured serially. A significant increase in tumor growth
was observed in LN229 glioblastoma cells overexpressing miR-29a (Mean ± SEM, *P < 0.05, unpaired t-test). b) Effect of miR-29a on PTEN expression in
LN229 glioblastoma cells or in primary glioblastoma stem-like cells transduced with a control or miR-29a lentivirus. c) Western blot illustrating effect of
miR-29a on PTEN expression and AKT phosphorylation (ser473) in LN229 glioblastoma cells transduced with a control or miR-29a lentivirus. d) Analysis
of PTEN copy number and microRNA expression data for 470 microRNAs. Data obtained from the TCGA portal for 197 glioblastoma specimens. Circled
area identifies miR-29a (PCC = 0.219), miR-29c (PCC = 0.260) and miR-29b (PCC = 0.228) as 3 of the top 4 microRNAs most positively correlated with
PTEN copy number in glioblastoma. Open arrow indicates location of miR-29a expression profile
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PTEN in glioblastoma suggests that miR-29a also
promotes glioblastoma invasion. Indeed, miR-29a has
recently been reported to enhance hepatoma cell migra-
tion by targeting PTEN [17]. However, many gliob-
lastomas lack functional PTEN, raising the question of
whether miR-29a differentially regulates invasion in
PTEN-competent and PTEN-deficient glioblastomas.
Exposure of human LN229 (PTEN-competent) or U251
(PTEN-deficient) glioblastoma cells to a miR-29a mimic
(100 nM) significantly increased glioblastoma cell inva-
sion by both cell lines in a 3-D Matrigel invasion assay
(Fig. 5A, B, P < 0.0001, unpaired t-test). In addition,
miR-29a increased invasion in primary glioblastoma
stem-like cells (Additional file 1: Figure S2). A miR-29a
antagomiR (100 nM) decreased invasion in both LN229
(P < 0.015, unpaired t-test) and U251 (P < 0.0001,
unpaired t-test) glioblastoma cells (Fig. 5C, D). Thus,
miR-29a promotes glioblastoma cell invasion in
PTEN-competent and PTEN-deficient glioblastomas.
Like PTEN, EphB3 suppresses AKT activation and in-
hibits lung cancer cell migration [37]. Although AKT acti-
vation can promote glioblastoma cell invasion, β-catenin
reportedly inhibits invasion in these cells [38]. Our finding
that miR-29a decreases expression of both PTEN and
EphB3 in glioblastoma raised the possibility that miR-29a
regulates a coordinated invasion program in glioblastoma.
We therefore searched for additional miR-29a targets that
might mediate its effects on glioblastoma invasion. Com-
putational analysis of microRNA and mRNA expression
profiles from 261 primary glioblastoma specimens identi-
fied Sox4 as the most anti-correlated predicted mRNA
target of miR-29a (PCC = − 0.636). Likewise, miR-29a was
Fig. 3 miR-29a increases proliferation and growth in glioblastoma cells lacking PTEN. a) Fluorescence micrographs (left panels) and data quantitation
(right panel) from BrdU proliferation assay investigating the effect of lentiviral-mediated miR-29a overexpression on BrdU (red) incorporation into
nuclei (DAPI, blue) by human U251 glioblastoma cells that lack functional PTEN. Data shown in right panel are mean ± SEM. *P < 0.0005, unpaired t-
test. Scale approximately 100 μm. b) Fluorescence micrographs (left panels) and quantitation (right panel) from BrdU proliferation assay illustrating the
effect of a miR-29a inhibitor (100 nM) on proliferation in PTEN-deficient U251 glioblastoma cells. P < 0.05, unpaired t-test. Data shown are mean ± SEM.
*P < 0.0005, unpaired t-test. Scale approximately 100 μm. c) MTT cell growth assay illustrating the effect of a specific miR-29a inhibitor (100 nM) on the
growth of PTEN-deficient U251 glioblastoma cells. Data shown are mean ± SEM. *P < 0.01, unpaired t-test
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the microRNA that was most anti-correlated with Sox4
(Additional file 1: Figure S3). Sox4 is an HMG box tran-
scription factor that regulates a variety of biological pro-
cesses, including neural differentiation [39]. Numerous
but conflicting reports indicate that Sox4 may act as either
an oncogene or a tumor suppressor in a range of cancers
[39]. Relevant to the current study is a previous report
that loss of Sox4 promotes melanoma cell invasion via a
mechanism that involves activation of NFκB [40, 41].
Western blot analysis indicated that miR-29a robustly
downregulates Sox4 protein expression in multiple hu-
man glioblastoma cell lines and in primary glioblastoma
stem-like cells (Fig. 6A), and the miR-29a inhibitor (100
nM) increased Sox4 protein levels in primary glioblast-
oma stem-like cells (Fig. 6B). Real-time PCR revealed a
miR-29a-induced decrease in Sox4 mRNA levels
(Additional file 1: Figure S1). Importantly, a luciferase
reporter assay in which the SOX4 3’-UTR was fused to
the firefly luciferase mRNA sequence indicated that
miR-29a directly targets the Sox4 3’UTR (Additional file
1: Figure S3).
We depleted endogenous Sox4 protein expression via
transient transfection of Sox4 siRNA in LN229 or U251
glioblastoma cells (Fig. 6C), and found that this signifi-
cantly increased glioblastoma cell invasion (Fig. 6D, P <
0.0001, unpaired t-test). Conversely, Sox4 overexpression
in PTEN-deficient U87 glioblastoma cells decreased inva-
sion (Fig. 6E, P < 0.01, unpaired t-test). Manipulation of
Sox4 expression did not increase AKT phosphorylation or
β-catenin levels (data not shown). Taken together, these
data indicate that miR-29a targets Sox4 to promote glio-
blastoma cell invasion independent of PTEN.
Fig. 4 miR-29a activates AKT and increases β-catenin in PTEN-deficient glioblastoma cells. a) Effect of miR-29a mimic (100 nM) or a scrambled
control mimic on AKT and β-catenin expression in PTEN-deficient U251 glioblastoma cells. b) Effect of miR-29a mimic (100 nM) or a control mimic
on GSK3β phosphorylation in PTEN-deficient U251 glioblastoma cells. c) Effect of miR-29a on EphB3 expression in U251, U87 or LN229
glioblastoma cells transduced with a control or a miR-29a lentivirus. d) Western blot illustrating effect of EphB3 siRNA on EphB3 expression and
AKT phosphorylation in LN229 glioblastoma cells. e) MTT assay illustrating effect of β-catenin overexpression on cell growth in human
glioblastoma cells. Data shown are mean ± SEM. *P < 0.05, unpaired t-test. f) MTT assay illustrating effect of the miR-29a mimic (100 nM) on
survival of U251 glioblastoma cells after camptothecin exposure (75 nM; mean ± SEM, *P < 0.006, unpaired t-test)
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HIC5 is a downstream mediator of the mir-29a/Sox4
invasion pathway in glioblastoma
Loss of Sox4 has been reported to promote invasion by ac-
tivating the NFκB pathway [40, 42]. However, the miR-29a
mimic failed to promote NFκB nuclear translocation in hu-
man glioblastoma cells, suggesting that NFκB activation is
not responsible for the miR-29a-induced increase in glio-
blastoma cell invasion (data not shown). To identify other
possible downstream mediators of the miR-29a/Sox4 inva-
sion pathway, we queried public databases [43, 44] to
search for Sox4 regulated transcripts that have been impli-
cated in cell migration or invasion. We identified HIC5
(a.k.a. TGFβ1I1) as a migration-related transcript [45–48]
that is upregulated after knockdown of Sox4 in other cell
types. Western blot analysis revealed upregulation of HIC5
protein expression after exposure of human U251
glioblastoma cells to the miR-29a mimic or after
siRNA-mediated knockdown of Sox4 (Fig. 6F). Knockdown
of HIC5 expression using siRNA significantly inhibited
LN229 (PTEN-competent) and U251 (PTEN-deficient)
glioblastoma cell invasion (Fig. 6G, *P < 0.0001, unpaired
t-test). Moreover, knockdown of HIC5 completely abro-
gated the increase in invasion induced by miR-29a in
PTEN-deficient U251 cells, suggesting that it plays an es-
sential role in this process (Fig. 6H).
miR-29a regulates glioblastoma invasion in vivo and
correlates with survival
Our earlier studies using human LN229 glioblastoma
cells transplanted subcutaneously unto nude mice indi-
cated that miR-29a promotes glioblastoma tumor growth
(see Fig. 2A). We next investigated the effect of
Fig. 5 miR-29a robustly increases invasion in PTEN-competent and PTEN-deficient glioblastoma cells. a) Phase micrographs of invading LN229 or
U251 glioblastoma cells in Matrigel invasion assay after exposure to control or miR-29a mimic (100 nM). Scale approximately 50 μm. b)
Quantitation of data depicted in a). Data shown are mean ± SEM of 6 replicates. *P < 0.05 for LN229 and *P < 0.0001 for U251 glioblastoma cells.
c) Phase micrographs of invading LN229 or U251 glioblastoma cells in Matrigel invasion assay after exposure to control or miR-29a inhibitor (100
nM). Scale approximately 50 μm. d) Quantitation of data depicted in c). Data shown are mean ± SEM of 6 replicates. *P < 0.01 for LN229 and *P <
0.0001 for U251 glioblastoma cells
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endogenous miR-29a on glioblastoma invasion in vivo
using an intracranial human glioblastoma xenograft
mouse model. PTEN-deficient human U251 glioblastoma
cells were transduced with a lentivirus containing a nu-
cleotide sequence complementary to miR-29a (miR-29a
sponge/miR-locker) or a control sequence (control
sponge/miR-locker), and a stable cell line was then se-
lected. The control and miR-29a sponge lentiviral vectors
also encoded either Red Fluorescent Protein (control) or
Green Fluorescent Protein (miR-29a), respectively. Over-
expression of the bulged miR-29a sponge sequence in-
creased mir-29a levels (Additional file 1: Figure S1),
presumably because it interfered with RISC-mediated deg-
radation of the miRNA/mRNA target duplex. The sponge
effectively antagonized the ability of miR-29a to degrade
its mRNA targets, as evidenced by the elevation of Sox4
mRNA (Additional file 1: Figure S1). This elevation was in
contrast to the decrease in Sox4 mRNA expression in-
duced by miR-29a itself (Additional file 1: Figure S1).
Overexpression of the miR-29a sponge increased Sox4
protein expression and decreased HIC5 protein expres-
sion in U251 glioblastoma cells (Fig. 7A). In addition, it
significantly decreased U251 glioblastoma cell prolifera-
tion (Fig. 7B, P < 0.02, unpaired t-test. The miR-29a
sponge also inhibited cell growth (P < 0.0001, unpaired
t-test) and increased DNA damage-induced apoptosis (P
< 0.05, unpaired t-test) in U251 glioblastoma cells in
vitro (Additional file 1: Figure S1).
Fig. 6 miR-29a activates a Sox4/HIC5 invasion pathway in glioblastoma. a) Effect of lentiviral-mediated overexpression of miR-29a on Sox4 expression in
LN229, U87, U251 or primary human glioblastoma stem-like cells (GSC). b) Effect of miR-29a antagomiR (100 nM) on Sox4 protein expression in primary
human glioblastoma stem-like cells. c) Western blot illustrating Sox4 knockdown using siRNA transfection in LN229 or U251 glioblastoma cells. d) Phase
micrographs (left panels) or quantitation of data (right panel) from a Matrigel invasion assay showing effect of siRNA-mediated Sox4 knockdown on LN229
or U251 glioblastoma cell invasion. Mean ± SEM. P< 0.0001, unpaired t-test. Scale approximately 50 μm. e) Phase micrographs (left panels) or data
quantitation (right panel) from a 3D Matrigel invasion assay showing effect of Sox4 overexpression on PTEN-deficient U87 glioblastoma cell invasion. Mean
± SEM; P< 0.01, unpaired t-test. Scale approximately 50 μm. f) Effect of miR-29a mimic or Sox4 siRNA on HIC5 protein expression in human U251
glioblastoma cells. g) Phase micrographs (left panels) or data quantitation (right panel) from a Matrigel invasion assay showing effect of siRNA-mediated
HIC5 knockdown on LN229 or U251 glioblastoma cell invasion. Mean ± SEM. *P< 0.0001, unpaired t-test. Scale approximately 50 μm. h) Phase micrographs
(left panels) or data quantitation (right panel) from a Matrigel invasion assay showing effect of siRNA-mediated HIC5 knockdown on invasion induced by
miR-29a in human U251 glioblastoma cells. Mean ± SEM. *P< 0.0001, unpaired t-test. Scale approximately 50 μm
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Inhibition of endogenous miR-29a using the miR-29a
sponge significantly decreased glioblastoma cell invasion
in vitro (Fig. 7C and Additional file 1: Figure S5). We ex-
amined the effect of miR-29a on glioblastoma cell
morphology using human U251 glioblastoma cells trans-
duced with control, miR-29a or miR-29a lentiviruses.
When compared to control U251 glioblastoma cells,
cells overexpressing miR-29a were smaller and displayed
moderately fewer filopodia (Fig. 7D). In contrast, cells
overexpressing the miR-29a sponge adopted a rounded
morphology with a marked reduction in filopodia and
lamellopodia (Fig. 7D).
In order to investigate the role of miR-29a in glioblast-
oma cell invasion in vivo, PTEN-deficient U251 glio-
blastoma cells expressing either the control (RFP) or
mir-29a (GFP) sponges were mixed 1:1 and injected
intracranially into the brains of nude mice. After one
week, the brains were collected and processed for
Fig. 7 Endogenous miR-29a regulates glioblastoma cell invasion in vivo and correlates with patient survival. a) Effect of miR-29a sponge
overexpression on Sox4 and HIC5 expression in human U251 glioblastoma cells. b) BrdU proliferation assay illustrating the effect of a miR-29a
sponge on U251 glioblastoma cell proliferation. Mean ± SEM. *P < 0.02, unpaired t-test. c) Matrigel invasion assay illustrating effect of miR-29a
sponge on U251 glioblastoma cell invasion. d) Fluorescence micrographs of U251 glioblastoma cells transduced with lentiviruses encoding miR-
29a, a miR-29a sponge or a control sequence. Scale approximately 3 μm. e) Fluorescence micrograph of mouse brain section obtained 1 week
after transplantation of U251 glioblastoma cells transduced with a control (red) or miR-29a sponge lentivirus. Scale approximately 500 μm. f)
Kaplan-Meier survival analyses using microRNA expression profiles (n = 197) or mRNA expression profiles (n = 504) obtained from the TCGA portal
for glioblastoma. P values are miR-29a (P = 0.038), SOX4 (P = 0.023), HIC5 (P = 0.027), EphB3 (P = 0.045)
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fluorescence imaging to identify invading cells. Glioblast-
oma cells overexpressing the miR-29a sponge (green
fluorescence) migrated from the injection site less than
control cells (red fluorescence, Fig. 7E).
Our initial observations using primary glioblastoma
specimens indicated that miR-29a is preferentially
expressed in the astrocytic and neural glioblastoma sub-
classes. Because these subclasses display the shortest
median survival among the five glioblastoma subclasses
identified by microRNA profiling, our findings suggested
that miR-29a may be associated with decreased patient
survival. Indeed, Kaplan-Meier survival analysis using
microRNA expression data from 261 primary glioblast-
oma specimens obtained from the TCGA portal indi-
cated that increased miR-29a expression is associated
with decreased patient survival (Fig. 7F, P = 0.038, Log-
rank). Consistent with the miR-29a/Sox4/HIC5 invasion
pathway identified by our in vitro studies, increased
Sox4 mRNA expression is positively correlated with pa-
tient survival (Fig. 7F, P = 0.023, Logrank), and HIC5
mRNA expression is negatively correlated with survival
(Fig. 7F, P = 0.027, Logrank). Of note, decreased EphB3
mRNA expression also correlated with decreased sur-
vival (Fig. 7F, P = 0.045, Logrank). Taken together, these
data establish a role for endogenous miR-29a in glio-
blastoma growth and invasion.
Discussion
MicroRNA-29a is a conserved microRNA that is involved
in the regulation of several coordinated post-transcriptional
programs affecting different biological processes. For ex-
ample, miR-29a represses the translation of multiple extra-
cellular matrix proteins, and miR-29a depletion leads to
fibrosis in several tissues [49]. miR-29a also regulates the
myeloid differentiation program [5]. We report here that
miR-29a regulates a complex program of cell growth and
invasion in glioblastoma. This program not only involves
co-activation of the AKT/PI3K and Wnt pathways via
downregulation of PTEN and EphB3, but also activation of
a newly discovered Sox4/Hic5 invasion pathway (Additional
file 1: Figure S6).
MicroRNA-29a has previously been reported to pro-
mote hepatoma cell migration by directly targeting
PTEN, a key regulator of migration in many cell types
[17, 50]. We observed that miR-29a robustly downregu-
lates PTEN in glioblastoma cells that have intact PTEN
function. Surprisingly, however, we did not find an
anti-correlation between miR-29a and PTEN mRNA ex-
pression. This may be due in part to the impact of other
mechanisms that regulate PTEN expression and function
in glioblastoma, including deletions, mutations and the
impact of other microRNAs [19, 27, 31, 32, 51]. Interest-
ingly, miR-29a is among the top 1% of microRNAs in
terms of its positive correlation with PTEN copy number
in glioblastoma, suggesting that miR-29a-mediated
downregulation of PTEN provides a selective growth ad-
vantage in glioblastoma cells with intact PTEN.
In many glioblastomas, PTEN is deleted or mutated
[51]. In such tumors, we find that miR-29a nevertheless
promotes growth by downregulating EphB3, thereby in-
creasing AKT activation and β-catenin levels. Activation
of the EphB3 receptor leads to PP2A-mediated dephos-
phorylation and inactivation of AKT [37]. Interestingly,
EphB3 also inhibits the migration of lung cancer cells [37].
Consistent with previous reports [34], we find that
AKT activation is accompanied by phosphorylation and
inactivation of GSK3β which, in turn, phosphorylates
β-catenin and targets it for degradation [35]. In osteo-
blasts, miR-29a has also been reported to increase
β-catenin by directly targeting several Wnt pathway an-
tagonists other than GSK3β [52]. Additional studies are
needed to determine whether miR-29a also increases
β-catenin via these mechanisms in glioblastoma.
In addition to the AKT/PI3 kinase and Wnt pathways,
miR-29a activates a newly-discovered Sox4/Hic5 inva-
sion pathway in glioblastoma cells. This pathway oper-
ates in PTEN-deficient glioblastoma cells to robustly
promote invasion. Sox4 is an HMG transcription factor
that promotes neuronal differentiation during nervous
system development [53]. Recent reports indicate that
decreased Sox4 expression promotes invasion in melan-
oma [39, 40]. This effect is thought to involve activation
of the NFκB pathway and regulation of DICER expres-
sion. In the current study, we did not find evidence for
miR-29a-induced nuclear translocation of NFκB, sug-
gesting that this is not the mechanism underlying
miR-29a-induced invasion in glioblastoma. However, we
did observe robust upregulation of HIC5 after miR-29a
exposure or Sox4 knockdown in glioblastoma cells.
Increased HIC5 expression promoted glioblastoma cell in-
vasion, and HIC5 knockdown abrogated the miR-29a-in-
duced increase in invasion. HIC5 is homologous to
paxillin and associates with the focal adhesion kinases,
FAK and Pyk2, at focal contacts [45, 46]. HIC5 has also
been reported to promote epithelial-to-mesenchymal tran-
sition (EMT) and invadopodia formation by regulating the
Rho/ROCK pathway [11, 47].
However, as a tumor promoter, miR-29 mediates
epithelial-mesenchymal transition (EMT) and promotes
metastasis in breast cancer, colon cancer and pancreatic
cancer [54–56]. There is also evidence that miR-29 may
regulate MMP2 or Mcl-1 [56, 57], which partly partici-
pate in the process of metastasis, yet the underlying
mechanisms remain controversial. Interestingly, we saw
no evidence of Rac1 activation by miR-29a (personal ob-
servations). Additional studies are thus underway to de-
termine the downstream signaling pathway activated by
HIC5 in glioblastoma cells.
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Conclusions
Our findings have potentially significant clinical implica-
tions. miR-29a expression is high in the astrocytic glio-
blastoma subclass, and this distinguishes this subclass
from the other mesenchymal glioblastoma subclass (i.e.
the neuromesenchymal subclass). Thus, miR-29a may
contribute to the decreased survival of patients with
glioblastomas from the astrocytic subclass. Sox4 is the
most anti-correlated predicted target of miR-29a in glio-
blastoma and is positively correlated with survival, while
HIC5 expression is upregulated by miR-29a or by de-
creased Sox4, and is anti-correlated with survival. This
pattern suggests that the miR-29a/Sox4/HIC5 invasion
pathway is functional in glioblastomas in vivo. Our find-
ing that miR-29a increases growth and invasion by
downregulating PTEN, EphB3 and Sox4 in glioblastoma
indicates the presence of a coordinated program pro-
moting tumor aggressiveness. Importantly, inhibition of
endogenous miR-29a decreases glioblastoma growth and
invasion in vivo. Thus, miR-29a may represent a new
therapeutic target in glioblastoma.
Additional file
Additional file 1: Figure S1. Effect of miR-29a on Sox4 mRNA. Figure
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cells. Figure S3. Sox4 is a miR-29a target. Figure S4. Effect of a miR-29a
sponge on glioblastoma cell growth. Figure S5. Effect of a miR-29a
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